An Oxford-based biotechnology firm has appointed a new non-executive director.

Laurence Espinasse began working at Oxford Biomedica, which is a leader in cell and gene therapy, on Wednesday last week (July 24).

Ms Espinasse has more than two decades of experience in the legal and healthcare sectors and is currently the general counsel and compliance officer at Institut Mérieux SA.

Institut Mérieux became a major shareholder in Oxford Biomedica, owning more than 10 per cent of the company’s shares, following the acquisition of ABL Europe, which is now known as Oxford Biomedica (France), in January.

Ms Espinasse said: "Following the acquisition of ABL Europe, I am honoured to be joining Oxford Biomedica’s board of directors.

"Institut Mérieux’s significant investment reflects our confidence in Oxford Biomedica’s potential.

"I look forward to working closely with the board to drive the next phase of growth."

Before joining Institut Mérieux, she was a partner and head of the business law department at MDL Société d’Avocats.

She obtained her professional lawyer’s certificate from the École des Avocats Centre Sud in Montpellier, France.

Dr Roch Doliveux, chair of Oxford Biomedica, said: "On behalf of the board, I am delighted to welcome Laurence Espinasse as non-executive director.

"Her vast legal experience will be a strong asset for the company as we look to build on significant commercial momentum and capitalise on the fast-growing cell and gene therapy sector."